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Objective: Trimetazidine (TMZ) has been used to protect against ischemia/reperfusion (I/R) 
injury of many tissues. We aimed to evaluate the effect of TMZ during retinal I/R in a guinea 
pig model.
Study design/patients and methods: An experimental study in retinal I/R. Three groups 
of five guinea pigs were studied to include a control, placebo, and drug test groups. Prior to 
the application of 90 minutes of high intraocular pressure (IOP) to induce retinal ischemia fol-
lowed by 24 hours of reperfusion, we applied intraperitoneal saline to the placebo group and 
3 mg/kg of TMZ for the drug test group and repeated the injections at intervals of six hours 
for four cycles. Both eyes of the animals were enucleated at the end of the reperfusion period. 
Biochemical assay and histopathologic evaluation was performed on one randomly selected eye 
of each animal. The level of retinal-free malondialdehyde (MDA) and retinal layer thicknesses 
were determined and comparisons were then made with the control group.
Results: The mean free MDA level increased in the placebo group (P = 0.006) but not in the drug 
group (P  0.05). We observed polymorphonucleated leukocyte infiltration, retinal edema and 
hydropic degeneration in the retina of the placebo group. However, significant histopathologic 
change was not observed in specimens of the drug group.
Conclusions: This study suggests TMZ has a beneficial effect on retinal lipid peroxidation and 
histopathologic changes due to I/R injury.
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Introduction
Trimetazidine (1(2,3,4-trimethoxyl-benzyl) piperazine HCl [TMZ]) was introduced 
several years ago as an anti-ischemic drug devoid of hemodynamic activity.1 TMZ has 
been reported as having antioxidant activity.2 TMZ positively influences the energy 
metabolism, it reduces the utilization of fatty acids in favour of carbohydrates, the 
toxicity of oxygen and the inflammatory process.3 TMZ has been demonstrated to limit 
acidosis and intracellular accumulation of sodium and calcium. A protective effect 
of TMZ on potassium permeability induced by oxygen free radicals has also been 
emphasized.4 TMZ inhibits platelet adhesion-aggregation, neutrophil infiltration and 
the generation or activity of oxygen-derived free radicals.5
Trimetazidine has been used to protect a variety of tissues from I/R injury including; 
myocardium, kidney, intestine, and liver.6–9 Free radicals play a role in the genesis of 
reperfusion-induced injury and that inhibition or scavengering of these highly cytotoxic 
intermediates may control potentially dangerous retinal injury.10 The protective effect 
of TMZ in retinal I/R injury has been previously reported.11Clinical Ophthalmology 2010:4 22
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According to its severity and duration retinal ischemia 
may result in the death of affected cells. Initially the ischemic 
retinal cells enter a phase of reversible injury, when timely 
reperfusion results in the survival of retinal cells that would 
otherwise die. Despite reperfusion, there is a direct correla-
tion with duration of ischemia and the degree of retinal cell 
death. The human retina is not resistant to ischemic injury. 
The condition is encountered in occlusions of the retinal 
artery and vein, diabetes, sickle cell disease, inflammatory 
diseases, and perhaps most dramatically in retinopathy of 
prematurity.12–15 Also a number of triggers, in addition to 
free radicals have been suggested to be responsible for the 
genesis of reperfusion induced retinal damage. These include; 
stimulation of the platelet activating factor, release of lyso-
phosphatides, and disturbances of potassium, sodium, and 
calcium conductance.10
In the present study, we examined the effects of acute 
retinal I/R injury in a guinea pig model and the effects of 
TMZ on this process.
Materials and methods
Fifteen male, pigmented guinea pigs weighing 420–580 g 
were selected for this study and were randomly divided into 
three groups. Ischemia and reperfusion were not induced and 
no drug was administered to the control group. During isch-
emia and reperfusion periods, normal saline and TMZ were 
administered to the placebo and drug groups, respectively.
Procedures used in this investigation conformed to the 
Animals in Ophthalmic and Vision Research (ARVO) state-
ment for the Use of the Animals in Ophthalmic and Vision 
Research. The animals were housed in wire-bottomed cages 
at room temperature with a 12-hour light–dark cycle. All 
animals were fed with standard rat chow although they were 
given only water 12 hours before surgery. Anesthesia was 
induced in the test animals using an intraperitoneal injection 
of 6% sodium pentobarbital (0.1 mL/100 g body weight). 
Proparacaine–HCl (0.05%) was administered as topical 
anesthetic to both eyes of the animals prior to surgical inter-
ventions. A previously described pressure induced retinal 
ischemia was performed in the placebo and drug groups.16 
Accordingly both anterior ocular chambers of each animal 
of the placebo and drug test groups were cannulated with a 
27 gauge needle connected to a bottle of normal saline and 
the bottle was rapidly lifted to a height of 205 cm in order 
to raise the intraocular pressure to 150 mmHg and sustained 
for 90 min Reperfusion was established by lowering the 
saline bottle to the eye level. The eyes were decanulated and 
underwent reperfusion for 24 hours. Normal saline (1 mL) 
and TMZ (Vastarel, Servier, France), 3 mg/kg were diluted 
with 3 mL 0.9% NaCl solution were injected intraperitone-
ally 15 minutes prior the induction of ischemia to the animals 
of the drug group. Similarly 4 mL of saline was injected 
intraperitoneally into animals of the placebo group. This 
was repeated every six hours for 24 hours (four in total). The 
dosage of TMZ was administered according to the model 
described by Ozden and colleagues.11 After the reperfu-
sion period of the placebo and drug groups, the animals 
were reanesthetized and both eyes of all the animals were 
enucleated. Similarly both eyes of the animals belonging to 
the control group were also enucleated. The animals were 
sacrificed by intracardiac thiopental sodium (50 mg/kg) at the 
end of the experiment. One eye of each animal was prepared 
for biochemical analysis and the other underwent histopatho-
logical evaluation. For biochemical analysis the enucleated 
eyes were immediately dissected coronally through the pars 
plana and after removal of the vitreous humor, the retinal 
tissue was dissected from the choroidea and stored at -80 °C 
until the biochemical assay was undertaken.
For determination of malondialdehyde (MDA) levels in 
the retinal tissue, the samples were homogenized. 50 mg of 
the homogenate was added to 0.1 mL of 0.5 M HClO4 and 
0.4 mL of distilled water. The addition of perchloric acid was 
necessary to precipitate proteins and release the MDA bound 
to the amino groups of proteins and other amino compounds. 
The samples were then centrifuged at 4500 × g for five min-
utes. Samples (20 µl) of the supernatant were separated using 
high-performance liquid chromatography (HPLC). HPLC 
separations were accomplished at room temperature, using a 
Cecil liquid chromatography system (Series 1100) consisting 
of a sample injection valve (Cotati 7125) with a 20 µl sample 
loop, an ultra-violet (UV, at 254 nm) spectrophotometric 
detector (Cecil 68174), integrator (HP 3395) and a Supelcosil 
LC18 (5 µm particle and 80 nm pore size) column (250 cm × 
4.6 mm ID) with mixture of 30 mmol KH2PO4 and methanol 
(in the ratio 65:35 the pH was adjusted to 4 using H3PO4), 
mobile phase at 1.5 mL minute-1 flow rate.17,18
Histopathologic evaluation was performed on sections 
obtained in the vertical meridian and the inferior portion of 
the eyeball without knowing which treatment was given. The 
sections were fixed in 10% formaline. Paraffin sections with 
5 µm thickness were prepared and stained with hematoxylin 
and eosin. Evaluation of the histopathologic specimens was 
by the pathologist conducting the trial without knowing 
which treatment was given using an Olympus BX50 light 
microscope and color photomicrographs were obtained. 
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was induced by I/R was made by measuring thickness of the 
retinal layers. The mean value for these measurements, taken 
in four adjacent areas of the inferior retina within 1 mm of the 
optic nerve, was calculated. The measurements were made 
with an ocular micrometer at 400 × magnification.
We presented the free MDA values and the tissue thick-
nesses of each group as the mean ± standard deviation (SD) 
and the statistical analysis was made using a Mann–Whitney 
U test. We considered a P value  0.05 as significant.
Results
The mean free MDA level of the control, the placebo and 
the drug groups was 5.13 ± 0.92, 9.45 ± 1.82 and 5.25 ± 
1.02 nmol MDA/g wet tissue, respectively. The mean free 
MDA level of the placebo group was significantly higher 
versus the control and drug groups (P = 0.004, P = 0.006, 
respectively). When we compared the control group with the 
drug group the mean free MDA level was not statistically 
different (P  0.05).
The thickness of the retinal layers of the groups is pre-
sented in Table 1 and Figure 1. The histopathologic speci-
mens of the control and the placebo group were compared. 
Observed differences were mainly in the inner retina of the 
placebo group. Prominent edema in the inner plexiform and 
ganglion cell layers, polymorphonuclear leucocyte (PMNL) 
infiltration and vacuolated spaces, hydropic degeneration, 
pyknosis particularly in the inner nuclear and ganglion cell 
layers were the main changes that were observed in the pla-
cebo group when compared to the control group (Figure 2). 
Additionally prominent edema was also observed in the outer 
plexiform and outer nuclear layers of the placebo group. 
Only mild edema was observed in the inner retina of the 
drug group (Figure 3).
The main findings observed in some histopathologic 
specimens of the drug group were mild edema of the 
photoreceptor, outer nuclear and inner plexiform layers and 
hydropic degeneration of a few cells in the inner nuclear 
and ganglion cell layers (Figure 3). The pathologic findings 
noticed in the placebo group were severe edema was observed 
mainly in the inner retina.
Discussion
During ischemia and reperfusion in a number of tissues 
such as intestine, central nervous system, and heart, oxygen-
derived free radicals are thought to play an important role 
in the genesis of tissue injury. Endogenous scavengering 
mechanisms may be overwhelmed by a burst of radical pro-
duction occurring during reperfusion or reoxygenation.19–22 
Primary ocular diseases or ocular complications of systemic 
diseases may cause retinal ischemia that results in cell death 
by the destruction of cellular elements such as DNA, protein, 
and cell membrane.23
As high fatty acid oxidation rates markedly decrease 
glucose oxidation, one approach to increase glucose oxida-
tion is to inhibit fatty acid oxidation. TMZ primarily acts by 
inhibiting fatty acid oxidation and thereby stimulating glucose 
oxidation. Earlier studies demonstrated that TMZ inhibits 
mitochondrial palmitoly carnitine oxidation, while only 
slightly altering pyruvate oxidation and preserving mitochon-
drial oxidative functions thereby significantly stimulating glu-
cose oxidation.24 Stimulation of glucose oxidation improves 
the coupling of glycolysis to glucose oxidation, resulting in 
a decrease in proton production and a decrease in intracel-
lular acidosis during ischemia.24 Charlton and colleagues25 
studied the possible antioxidant effects of TMZ by using rat 
hearts that were perfused in ischemic conditions. The oxida-
tive damage was measured in terms of enzymatic activity 
of MDA and MDA levels were found to decrease in their 
study. In the present study TMZ has inhibited the increase in 
MDA values of the retinal tissue which has undergone I/R. 
TMZ has also been reported to reduce the tissue formation of 
MDA.26 It reduces the oxidative stress which occurs during 
the reoxygenation phase of the reperfusion, evaluated as a 
limited reduction in glutathione release.27
In order to determine thresholds for irreversible cel-
lular injury in the rat retina, timed acute no flow ischemic 
episodes of 30–180 minutes duration were produced by 
elevation of intraocular pressure (IOP) above systolic pres-
sure. Quantitation of irreversible degeneration and cell loss 
following a two-week postischemic interval was performed 
by computer assisted measurements from histologic sections. 
Table 1 The thickness of the retinal layers (µm)
Groups GCL IPL INL OPL ONL PL
Control 8.0 ± 1.42 14 ± 1.85 10.75 ± 1.672 7.0 ± 1.67 12.0 ± 2.09 13.0 ± 3.26
Placebo 14.25 ± 1.121 20.2 ± 3.581 17.25 ± 1.85 12.25 ± 1.01 15.85 ± 1.021 18.25 ± 3.791
Drug 9.0 ± 2.05 15.5 ± 2.09 11.75 ± 1.893 8.5 ± 1.36 14.5 ± 1.89 15.25 ± 1.85
Notes: 1P  0.05 for placebo vs drug and control, 2P  0.01 for placebo vs control, 3P  0.05 for placebo vs drug.
Abbreviations: gCL, ganglion cell layer; iPL, inner plexiform layer; inL, inner nuclear layer; OPL, outer plexiform layer; OnL, outer nuclear layer; PL, photoreceptor layer.Clinical Ophthalmology 2010:4 24
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Figure 2 Placebo: Microphotograph of degeneration of retinal ganglion cells (broken arrow), edema of inner plexiform layer (long arrow), pyknotic cells in inner nuclear 
layer (short arrow) and polymorphonuclear leukocytes (thick arrow).
Notes: hematoxylin and eosin 400 × magnification.
Figure 1 The graphical changes of thickness of the retinal layers.
Abbreviations: gCL, ganglion cell layer; iPL, inner plexiform layer; inL, inner nuclear layer; OPL, outer plexiform layer; OnL, outer nuclear layer; PL, photoreceptor layer.
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Changes of thickness of retinal layers and linear cell density 
were determined for ischemia of selected durations.15 
A reduction in the retinal thickness has been reported in a 
recent study in which eight days of reperfusion period was 
performed. Nevertheless, increase in the retinal thickness due 
to retinal edema has been described in animal studies with 
reperfusion periods of 24 hours or shorter duration after an 
ischemic period of 90 minutes.28,29 The result of our study, 
indicating the increase in the retinal thickness, is consistent 
with studies in which 24 hours or shorter reperfusion periods Clinical Ophthalmology 2010:4 25
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Figure 3 Drug: histological photograph of hydropic degeneration of a few ganglion cells (broken arrow), slight edema of inner plexiform layer (long arrow), and hydropic 
degeneration of a few cells in inner nuclear layer (short arrow).
Notes: hematoxylin and eosin 400 × magnification.
have been been set up. TMZ has been demonstrated to 
limit the intracellular accumulation of sodium and calcium. 
A protective effect of TMZ on potassium permeability 
induced by oxygen free radicals has also been emphasized.4 
We considered TMZ limited edema formation in retina by 
stabilizing intracellular electrolyte levels and due to its anti-
inflammatory action. We observed significant histopathologic 
changes in the inner nuclear and ganglion cell layers of the 
placebo group similar to a previous study in which depletion 
of cytoplasmic organelles, swelling of mitochondria and 
enlargement of endoplasmic reticulum have been observed 
in the ganglion cells by electron microscopy after retinal 
ischemia.30 When the ischemic duration was extended to 
60 minutes, reperfusion of the previously ischemic retina 
increased the edema formation in the inner plexiform layer. 
Increasing the ischemia to 90 min caused serious retinal 
edema, observed at a maximum value even after 24 hours 
of reperfusion.10
Under certain conditions of altered physiology, the neu-
trophil leukocytes may react in a manner that leads to tissue 
injury. The tissue damage resulting from retinal ischemia 
activates a cascade of events which represents an inflamma-
tory response that occurs independently of any improvement 
in retinal reoxygenation.31 The inflammatory reaction is an 
important source of oxygen-free radicals. Large amounts 
of superoxide radicals are secreted by activated phagocytic 
leukocytes and radicals are also formed as a byproduct 
during prostaglandin and leukotriene biosynthesis.19 TMZ 
reduces the infiltration of neutrophils in the risk area.26 Szabo 
and colleagues29 demonstrated that neutrophil leukocyte 
infiltration could be observed after 90 minures of ischemia 
followed by 24 hours of reperfusion in the rat retina. In 
addition, antioxidant agents could significantly reduce the 
incidence of neutrophil leukocyte infiltration. Histopatho-
logic changes such as severe edema, vacuolated spaces and 
PMNL infiltration mainly in the inner retina of the placebo 
group are consistent with our findings. It was reported that 
TMZ could have a favorable effect on myocardial ischemia 
by reducing neutrophil leukocyte infiltration which, in turn 
is responsible for myocardial necrosis.25 In a previous study 
no neutrophil infiltration in the retinal tissue was observed in 
any of the TMZ-treated rats.11 TMZ’s mechanism of action 
on the infiltration of neutrophils is still unclear. Because 
the neutrophil penetration depends on chemotactic agents 
and the expression of adhesion molecules stimulated by 
cytokines.
In conclusion, TMZ has a significant role in combatting 
the consequences of retinal lipid peroxidation and it dimin-
ishes the formation of retina edema and degenerative changes 
during ischemia and reperfusion. Although the sample size 
might be considered as a limitation of the present study, our 
results indicate the clinical application of TMZ in retinal Clinical Ophthalmology 2010:4
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vascular pathologies related to ischemia and reperfusion 
injury may have beneficial effects.
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